Literature DB >> 11888668

Involvement of the mt1 melatonin receptor in human breast cancer.

P T Ram1, J Dai, L Yuan, C Dong, T L Kiefer, L Lai, S M Hill.   

Abstract

Two putative melatonin receptors have been described including the cell surface G-protein-linked receptors, mt1 and MT2, and the nuclear retinoic orphan receptor alpha (RORalpha). The mt1 receptor, but not the MT2 receptor, is expressed in human breast tumor cell lines, and melatonin-induced growth suppression can be mimicked by the mt1 and MT2 agonist, AMMTC, and blocked by the antagonist, CBPT. RORalpha receptors are also expressed in MCF-7 breast cancer cells and the putative RORalpha agonist CPG-52608 inhibits MCF-7 cell growth but with a very different dose-response than melatonin. Finally, melatonin and AMMTC, but not CPG-52608, can repress RORalpha transcriptional activity in MCF-7 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888668     DOI: 10.1016/s0304-3835(01)00873-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  37 in total

Review 1.  Melatonin membrane receptors in peripheral tissues: distribution and functions.

Authors:  Radomir M Slominski; Russel J Reiter; Natalia Schlabritz-Loutsevitch; Rennolds S Ostrom; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

Review 2.  Melatonin: an inhibitor of breast cancer.

Authors:  Steven M Hill; Victoria P Belancio; Robert T Dauchy; Shulin Xiang; Samantha Brimer; Lulu Mao; Adam Hauch; Peter W Lundberg; Whitney Summers; Lin Yuan; Tripp Frasch; David E Blask
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

Review 3.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

4.  Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II.

Authors:  Susan B Brown; Susan E Hankinson; A Heather Eliassen; Katherine W Reeves; Jing Qian; Kathleen F Arcaro; Lani R Wegrzyn; Walter C Willett; Eva S Schernhammer
Journal:  Am J Epidemiol       Date:  2015-01-13       Impact factor: 4.897

5.  Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells.

Authors:  P Plaimee; N Weerapreeyakul; S Barusrux; N P Johns
Journal:  Cell Prolif       Date:  2015-02       Impact factor: 6.831

Review 6.  Functional MT1 and MT2 melatonin receptors in mammals.

Authors:  Margarita L Dubocovich; Magdalena Markowska
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 7.  Circulating melatonin and the risk of breast and endometrial cancer in women.

Authors:  Akila N Viswanathan; Eva S Schernhammer
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

8.  Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature.

Authors:  Michelle Basler; Alexander Jetter; Daniel Fink; Burkhardt Seifert; Gerd A Kullak-Ublick; Andreas Trojan
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

Review 9.  Molecular mechanisms of melatonin's inhibitory actions on breast cancers.

Authors:  Sara Proietti; Alessandra Cucina; Russel J Reiter; Mariano Bizzarri
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

10.  Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.

Authors:  C Martínez-Campa; A González; M D Mediavilla; C Alonso-González; V Alvarez-García; E J Sánchez-Barceló; S Cos
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.